For US Healthcare Professionals Important Safety Information Full Prescribing Information

Mechanism of Action

CroFab Rapidly Binds to and Neutralizes Venom Toxins1

Watch this video to see how CroFab works.


Upon Administration, CroFab Gets to Work

CroFab is specifically designed to contain a spectrum of venom-specific Fab fragments targeting the range of complex toxins found in North American pit viper venoms.1

Complex array of toxins in North American pit viper venom

Envenomation

North American pit viper venom contains a complex array of toxins that can result in a range of local, systemic, and/or hematologic effects2,3

Venom specific Fab fragments in CroFab neutralizing venom toxins

Rapid Neutralization

The small size of venom-specific protein (Fab) fragments permits a rapid, large volume of distribution into tissue, allowing faster neutralization of venom toxins4

Rapid clearance of venom and Fab fragments of CroFab

Rapid Clearance

Small protein (Fab) fragments also permit faster clearance, allowing for decreased immune system recognition and low incidence of hypersensitivity4

CroFab efficacy checkmark icon

CroFab is clinically proven to achieve initial control of envenomation2

Examine the Data
 IgG antibody icon

A proven manufacturing process ensures only the most effective and highest quality venom-specific antibodies1,5

Review How CroFab Is Made
CroFab dosing vial icon

Appropriate dosing achieves initial and sustained control of envenomation1

Learn How to Dose CroFab
REFERENCES

1. CroFab® [prescribing Information]. BTG International Inc.; August 2018. 2. Ruha AN, Kleinschmidt KC, Greene S, et al; ToxIC Snakebite Study Group. The epidemiology, clinical course, and management of snakebites in the North American Snakebite Registry. J Med Toxicol. 2017;13(4):309-320. 3. Gutiérrez JM, Calvete JJ, Habib AG, Harrison RA, Williams DJ, Warrell DA. Snakebite envenoming. [Erratum in: Nat Rev Dis Primers. 2017;3:17079]. Nat Rev Dis Primers. 2017;3:17063. 4. Laustsen AH, María Gutiérrez J, Knudsen C, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. 2018;146:151-175. 5. Data on file. BTG International Inc.